Literature DB >> 21598253

Peroxisome proliferator-activated receptor β/δ (PPARβ/δ) is highly expressed in liposarcoma and promotes migration and proliferation.

Kay-Dietrich Wagner1, Maxime Benchetrit, Laurence Bianchini, Jean-François Michiels, Nicole Wagner.   

Abstract

Aberrations of specialized metabolic pathways might be implicated in the development of neoplasias. Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors with important functions in metabolism. PPARβ/δ and PPARγ act in the proliferation and differentiation of adipose tissue progenitor cells. Thus, a potential use of PPARγ agonists for the treatment of liposarcoma had been suggested, but clinical trials failed to detect beneficial effects. We show here that PPARδ is highly expressed in liposarcoma compared to lipoma and correlates with proliferation. Stimulation of liposarcoma cell lines with a specific PPARδ agonist increases proliferation, which is abolished by a PPARδ-siRNA or a specific PPARδ antagonist. Expression of the adipose tissue secretory factor leptin is lower in liposarcoma compared to lipoma and leptin reduces proliferation of liposarcoma cell lines. PPARδ activation stimulates cell migration whereas leptin diminishes it. We demonstrate that PPARδ directly represses leptin as: (a) leptin becomes down-regulated upon PPARδ activation; (b) PPARδ represses leptin promoter activity in different sarcoma cell lines; (c) deletion of a PPAR/RxR binding element in the leptin promoter abolishes repression by PPARδ; and (d) in chromatin immunoprecipitation we confirm in vivo binding of PPARδ to the leptin promoter. Our data suggest inhibition of PPARδ as a potential novel strategy to reduce liposarcoma cell proliferation.
Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21598253     DOI: 10.1002/path.2910

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  16 in total

1.  Hematopoietic knockdown of PPARδ reduces atherosclerosis in LDLR-/- mice.

Authors:  G Li; C Chen; S D Laing; C Ballard; K C Biju; R L Reddick; R A Clark; S Li
Journal:  Gene Ther       Date:  2015-08-23       Impact factor: 5.250

Review 2.  Peroxisome Proliferator-Activated Receptors and the Hallmarks of Cancer.

Authors:  Nicole Wagner; Kay-Dietrich Wagner
Journal:  Cells       Date:  2022-08-05       Impact factor: 7.666

3.  Genetic ablation of the fatty acid-binding protein FABP5 suppresses HER2-induced mammary tumorigenesis.

Authors:  Liraz Levi; Glenn Lobo; Mary Kathryn Doud; Johannes von Lintig; Darcie Seachrist; Gregory P Tochtrop; Noa Noy
Journal:  Cancer Res       Date:  2013-05-30       Impact factor: 12.701

Review 4.  Establishing the Role of PPARβ/δ in Carcinogenesis.

Authors:  Jeffrey M Peters; Frank J Gonzalez; Rolf Müller
Journal:  Trends Endocrinol Metab       Date:  2015-10-18       Impact factor: 12.015

5.  Mechanisms of vascular dysfunction in mice with endothelium-specific deletion of the PPAR-δ gene.

Authors:  Livius V d'Uscio; Tongrong He; Anantha Vijay R Santhanam; Li-Jung Tai; Ronald M Evans; Zvonimir S Katusic
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-01-31       Impact factor: 4.733

6.  Leptin, Acting at Central Level, Increases FGF21 Expression in White Adipose Tissue via PPARβ/δ.

Authors:  Lorena Mazuecos; Cristina Pintado; Blanca Rubio; Eduardo Guisantes-Batán; Antonio Andrés; Nilda Gallardo
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

7.  PPARδ regulates satellite cell proliferation and skeletal muscle regeneration.

Authors:  Alison R Angione; Chunhui Jiang; Dongning Pan; Yong-Xu Wang; Shihuan Kuang
Journal:  Skelet Muscle       Date:  2011-11-01       Impact factor: 4.912

Review 8.  Advances in the targeted therapy of liposarcoma.

Authors:  Zhonghai Guan; Xiongfei Yu; Haohao Wang; Haiyong Wang; Jing Zhang; Guangliang Li; Jiang Cao; Lisong Teng
Journal:  Onco Targets Ther       Date:  2015-01-05       Impact factor: 4.147

9.  Novel systemic therapies in advanced liposarcoma: a review of recent clinical trial results.

Authors:  William W Tseng; Neeta Somaiah; Alexander J Lazar; Dina C Lev; Raphael E Pollock
Journal:  Cancers (Basel)       Date:  2013-05-10       Impact factor: 6.639

10.  Cross-enhancement of ANGPTL4 transcription by HIF1 alpha and PPAR beta/delta is the result of the conformational proximity of two response elements.

Authors:  Tsuyoshi Inoue; Takahide Kohro; Toshiya Tanaka; Yasuharu Kanki; Guoliang Li; Huay-Mei Poh; Imari Mimura; Mika Kobayashi; Akashi Taguchi; Takashi Maejima; Jun-ichi Suehiro; Akira Sugiyama; Kiyomi Kaneki; Hirofumi Aruga; Shoulian Dong; Junko F Stevens; Shogo Yamamoto; Shuichi Tsutsumi; Toshiro Fujita; Xiaoan Ruan; Hiroyuki Aburatani; Masaomi Nangaku; Yijun Ruan; Tatsuhiko Kodama; Youichiro Wada
Journal:  Genome Biol       Date:  2014-04-10       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.